Treatment of
Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.
1. A pharmaceutical composition comprising a purified bacterial mixture consisting of 7 to 10 bacterial strains, wherein at least 7 of the bacterial strains comprise 16S rDNA sequences of at least 97% sequence identity to sequences independently selected from the group consisting of SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21; wherein the bacterial strains are lyophilized.
2. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.
4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of a capsule.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for delivery to the colon.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises one or more enteric polymers.
7. A method of treating a Clostridium difficile infection in a subject, the method comprising administering the pharmaceutical composition of claim 1 to the subject in an amount sufficient to treat the Clostridium difficile infection.
8. The method of claim 7 , wherein the Clostridium difficile infection is a first occurrence of the Clostridium difficile infection.
9. The method of claim 7 , wherein the Clostridium difficile infection is a recurrent Clostridium difficile infection.
10. The method of claim 7 , wherein the subject has been treated with an antibiotic prior to recurrence of the Clostridium difficile infection.
11. The method of claim 7 , further comprising administering an antibiotic to the subject.
12. A method to suppress an abnormal or excessive immune response in a subject comprising administering the pharmaceutical composition of claim 1 to the subject in an amount sufficient to suppress the abnormal or excessive immune response.
13. The method of claim 12 , wherein the abnormal or excessive immune response is suppressed by inducing proliferation and/or accumulation of regulatory T cells.
14. The method of claim 12 , wherein the subject is administered one or more doses of an antibiotic prior to the pharmaceutical composition.
15. The method of claim 14 , wherein the antibiotic is vancomycin, kanamycin, gentamicin, colistin, metronidazole, clindamycin, fidaxomicin, or cefoperazone.
16. The method of claim 14 , wherein the antibiotic is vancomycin.
17. A pharmaceutical composition comprising a purified bacterial mixture consisting of 7 to 10 bacterial strains, wherein at least 7 of the bacterial strains comprise 16S rDNA sequences of at least 97% sequence identity to sequences independently selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO:20, and SEQ ID NO:21; and one or more enteric polymers; wherein the pharmaceutical composition comprises between 1×10 7 and 1×10 10 colony forming units (CFUs) per bacterial strain; and wherein the pharmaceutical composition is in the form of a capsule.
18. The pharmaceutical composition of claim 17 , further comprising a pharmaceutically acceptable excipient.
19. The pharmaceutical composition of claim 17 , wherein the pharmaceutical composition is formulated for oral administration.
20. The pharmaceutical composition of claim 17 , wherein the pharmaceutical composition is formulated for delivery to the colon.
21. A method of treating a Clostridium difficile infection in a subject, the method comprising administering the pharmaceutical composition of claim 17 to the subject in an amount sufficient to treat the Clostridium difficile infection.
22. The method of claim 21 , wherein the Clostridium difficile infection is a first occurrence of the Clostridium difficile infection.
23. The method of claim 21 , wherein the Clostridium difficile infection is a recurrent Clostridium difficile infection.
24. The method of claim 21 , wherein the subject has been treated with an antibiotic prior to recurrence of the Clostridium difficile infection.
25. The method of claim 21 , further comprising administering an antibiotic to the subject.
26. A method to suppress an abnormal or excessive immune response in a subject comprising administering the pharmaceutical composition of claim 17 to the subject in an amount sufficient to suppress the abnormal or excessive immune response.
27. The method of claim 26 , wherein the abnormal or excessive immune response is suppressed by inducing proliferation and/or accumulation of regulatory T cells.
28. The method of claim 26 , wherein the subject is administered one or more doses of an antibiotic prior to the pharmaceutical composition.
29. The method of claim 28 , wherein the antibiotic is vancomycin, kanamycin, gentamicin, colistin, metronidazole, clindamycin, fidaxomicin, or cefoperazone.
30. The method of claim 28 , wherein the antibiotic is vancomycin.